To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors
This study includes 2 parts. Part 1 is a safety run-in stage and part 2 is to assess the efficacy and safety of tislelizumab in combination with lenvatinib
Advanced Solid Tumor
DRUG: lenvatinib|DRUG: Tislelizumab
Part 1: Percentage of Participants Reporting One or More Dose-Limiting Toxicities (DLTs) Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Up to 28 days in Part 1|Part 1: Number of Participants with Clinically Significant physical examinations, electrocardiograms (ECGs), and laboratory assessments, Up to 28 days in Part 1|Part 2: Overall response rate (ORR), Defined as the proportion of participants who achieved complete response (CR), or partial response (PR) as assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, up to approximately 3.5 years
Progression-Free Survival (PFS), PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first, up to approximately 3.5 years|Duration Of Response (DOR), DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death, up to approximately 3.5 years|Disease Control Rate (DCR), DCR is defined as the percentage of participants who have shown Complete Response (CR), Partial Response (PR), or Stable Disease (SD) as the best overall response in accordance with the RECIST version 1.1 criteria., up to approximately 3.5 years|Overall Survival (OS), OS defined as the time from start of treatment to the date of death due to any cause, up to approximately 3.5 years|Part 2: Proportion of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), up to approximately 3.5 years
This study includes 2 parts. Part 1 is a safety run-in stage and part 2 is to assess the efficacy and safety of tislelizumab in combination with lenvatinib